RxDoctor Payments DataLook up a doctor →

Andrew Garza, PA

Medical · Dallas, TXNPI 1104561281

Payments from drug & device makers

$43,053in general payments, 2019–2025

Across 919 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$17K
  • Medtronic$9K
  • Abbott$3K
  • Amgen$2K
  • Corcept Therapeutics$2K
  • Lilly USA, LLC$2K
  • plus $8K from 36 others
$2,142in research payments, 2019–2025

Across 8 payments — averaging $267.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$2K

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insulet Corporation92$17,424
Medtronic95$9,469
Abbott65$2,788
Amgen(2 entities)110$2,020
Corcept Therapeutics60$1,982
Lilly USA, LLC93$1,617
Mannkind Corporation55$1,154
Novo Nordisk40$1,022
Xeris Pharmaceuticals, Inc.50$859
Bayer61$668
Sequel Med Tech, LLC16$364
BETA Bionics, Inc.8$333
Radius Health, Inc.16$321
Sanofi-aventis U.S. LLC15$317
Dexcom, Inc.15$267
Boehringer Ingelheim13$245
AbbVie13$238
Astellas Pharma US Inc7$235
Cequr Corporation3$185
Madrigal Pharmaceuticals12$167
Ascendis Pharma Endocrinology Inc8$166
Intuity Medical Inc16$156
Esperion Therapeutics, Inc.8$150
Amneal Pharmaceuticals LLC8$129
AstraZeneca(2 entities)6$123
Tandem Diabetes Care, Inc.6$107
Merck4$72
Amarin Pharma, Inc.3$61
Averitas Pharma Inc.2$56
IBSA Pharma Inc.3$54
Verity Pharmaceuticals Inc.2$49
Alvogen Inc2$48
Amphastar Pharmaceuticals, Inc.2$35
Halozyme Inc2$30
Recordati_rare_diseases_inc.1$27
Novartis1$19
Esteve Pharmaceuticals LLC1$18
Tolmar, Inc.1$16
Ascensia Diabetes Care US Inc.1$15
Lifescan, Inc.1$15
Nevro Corp.1$15
Antares Pharma, Inc.1$14

How this compares

$43,053 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas →

Medicare billing

Part B allowed, 2024
$13,311
Medicare patients
67
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →